An Analysis of Bevacizumab or Cetuximab for CRC

Aumolertinib improved progression-free survival vs placebo in patients with unresectable stage III non–small cell lung cancer, according to data from an interim analysis of the phase 3 POLESTAR trial.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ivonescimab outperforming pembrolizumab in PD-L1-positive advanced non-small cell lung cancer.

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

In separate, live virtual events, Doris Hansen, MD, and Leyla O. Shune, MD, discuss options for a patient with relapsed/refractory multiple myeloma and how often participants use chimeric antigen receptor (CAR) T-cell therapy.

Janet L. Abrahm, MD, FACP, FAAHPM, discussed the high rates of oncologist burnout and compassion fatigue.